The Form 4 filing, an SEC report of insider stock activity, was filed on November 18, 2026. It identifies ORBIMED ADVISORS LLC as a director and 10% owner of WWB, the ticker for Windward Bio Group AG. The purchase took place on November 16, 2026.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-16 |
| Date of Latest Transaction | 2026-11-16 |
| Buy/Sell | buy |
| Transaction Count | 1 |
| Shares Transacted | 1,176,471 |
| Price | $17.00 |
| Total Transaction Value | $20,000,007.00 |
| Insider | |
| Ticker Symbol | WWB |
| Company | WINDWARD BIO GROUP AG |
| Insider Name | ORBIMED ADVISORS LLC |
| Insider Title | Director, 10% Owner |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 1,708,103 |
| Position Size Change | 68.88% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a share purchase, reported with transaction code P. ORBIMED ADVISORS LLC bought shares of Windward Bio Group AG in one transaction. The available details do not show whether the purchase took place on an exchange or through a private deal.
What was the average price of the transaction?
The average price was $17.00 per share. That price applies to the one purchase reported for November 16, 2026.
How did this transaction affect the insider's holdings?
The purchase added 1,176,471 shares, leaving 1,708,103 shares reported as owned afterward. The shares bought made up 68.88% of that reported balance after the trade.
What's the total transaction value?
The total transaction value was $20,000,007.00 for the single transaction. That amount matches the reported 1,176,471 shares bought at $17.00 each.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement. No filing footnotes were provided, so any further terms or explanations remain unknown. The information does not establish why the purchase was made.
Source: SEC Form 4 filing.
For research purposes only; not investment advice.